Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection
Existing tumor markers for testicular germ cell tumor (TGCT) cannot detect the presence of pure teratoma. Serum miRNAs have strong performance detecting other subtypes of TGCT. Previous reports suggest high levels of miR-375 expression in teratoma tissue. The purpose of this study was to explore the...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-04-01
|
| Series: | European Urology Open Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666168321000380 |
| _version_ | 1818574151524286464 |
|---|---|
| author | John T. Lafin Alexander P. Kenigsberg Xiaosong Meng Dreaux Abe Anna Savelyeva Nirmish Singla Solomon L. Woldu Yair Lotan Ryan J. Mauck Cheryl M. Lewis Vitaly Margulis Daniel Wong Liwei Jia Payal Kapur Lin Xu Ryan W. Speir Gregory T. Chesnut A. Lindsay Frazier Douglas W. Strand Nicholas Coleman Matthew J. Murray James F. Amatruda Aditya Bagrodia |
| author_facet | John T. Lafin Alexander P. Kenigsberg Xiaosong Meng Dreaux Abe Anna Savelyeva Nirmish Singla Solomon L. Woldu Yair Lotan Ryan J. Mauck Cheryl M. Lewis Vitaly Margulis Daniel Wong Liwei Jia Payal Kapur Lin Xu Ryan W. Speir Gregory T. Chesnut A. Lindsay Frazier Douglas W. Strand Nicholas Coleman Matthew J. Murray James F. Amatruda Aditya Bagrodia |
| author_sort | John T. Lafin |
| collection | DOAJ |
| description | Existing tumor markers for testicular germ cell tumor (TGCT) cannot detect the presence of pure teratoma. Serum miRNAs have strong performance detecting other subtypes of TGCT. Previous reports suggest high levels of miR-375 expression in teratoma tissue. The purpose of this study was to explore the role of serum miRNA, including miR-375, in detecting the presence of teratoma at postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).We prospectively collected presurgical serum from 40 TGCT patients undergoing PC-RPLND (21 with teratoma at RPLND and 19 with no evidence of disease). We examined the utility of serum miR-375-3p and miR-375-5p by quantitative polymerase chain reaction, and searched for other putative serum miRNAs with small RNA sequencing. The area under the receiver operating characteristic curve (AUC) and univariate analyses were utilized to evaluate test characteristics and predictors of teratoma.Both serum miR-375-3p and miR-375-5p exhibited poor performance (miR-375-3p: 86% sensitivity, 32% specificity, AUC: 0.506; miR-375-5p: 55% sensitivity, 67% specificity, AUC: 0.556). Teratoma at orchiectomy was the only predictor of PC-RPLND teratoma. Small RNA sequencing identified three potentially discriminatory miRNAs, but further validation demonstrated no utility. Our results confirm prior reports that serum miR-375 cannot predict teratoma, and suggest that there may not exist a predictive serum miRNA for teratoma. Patient summary: We found that serum miR-375 cannot detect the presence of teratoma at postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). We are also unable to find any other serum miRNAs predictive of pure teratoma at PC-RPLND. Hence, the lack of a reliable circulating marker of teratoma remains a critical clinical need. |
| first_indexed | 2024-12-15T00:22:39Z |
| format | Article |
| id | doaj.art-1e906041cff244ba8e0c12744972018d |
| institution | Directory Open Access Journal |
| issn | 2666-1683 |
| language | English |
| last_indexed | 2024-12-15T00:22:39Z |
| publishDate | 2021-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | European Urology Open Science |
| spelling | doaj.art-1e906041cff244ba8e0c12744972018d2022-12-21T22:42:15ZengElsevierEuropean Urology Open Science2666-16832021-04-01268387Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node DissectionJohn T. Lafin0Alexander P. Kenigsberg1Xiaosong Meng2Dreaux Abe3Anna Savelyeva4Nirmish Singla5Solomon L. Woldu6Yair Lotan7Ryan J. Mauck8Cheryl M. Lewis9Vitaly Margulis10Daniel Wong11Liwei Jia12Payal Kapur13Lin Xu14Ryan W. Speir15Gregory T. Chesnut16A. Lindsay Frazier17Douglas W. Strand18Nicholas Coleman19Matthew J. Murray20James F. Amatruda21Aditya Bagrodia22Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USADepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USADepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USADepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USADepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USADepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USADepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USADepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USADepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USAHarold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USADepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, I.M. Sechenov First Moscow State University, Moscow, RussiaDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USADepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USADepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USAQuantitative Biomedical Research Center, Department of Population & Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USADepartment of Urology, Madigan Army Medical Center, Tacoma, WA, USADepartment of Urology, Walter Reed National Military Medical Center, Bethesda, MD, USA; Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USADana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USADepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USADepartment of Pathology, University of Cambridge, Cambridge, UK; Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UKDepartment of Pathology, University of Cambridge, Cambridge, UK; Department of Pediatric Hematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UKCancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA; Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USADepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Corresponding author. Department of Urology, University of Texas Southwestern Medical Center, 2001 Inwood Rd, WCBE3, 4th floor, Dallas, TX 75390-9110, USA. Tel. +1 214 645-8765; Fax: +1 214-648-8786.Existing tumor markers for testicular germ cell tumor (TGCT) cannot detect the presence of pure teratoma. Serum miRNAs have strong performance detecting other subtypes of TGCT. Previous reports suggest high levels of miR-375 expression in teratoma tissue. The purpose of this study was to explore the role of serum miRNA, including miR-375, in detecting the presence of teratoma at postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).We prospectively collected presurgical serum from 40 TGCT patients undergoing PC-RPLND (21 with teratoma at RPLND and 19 with no evidence of disease). We examined the utility of serum miR-375-3p and miR-375-5p by quantitative polymerase chain reaction, and searched for other putative serum miRNAs with small RNA sequencing. The area under the receiver operating characteristic curve (AUC) and univariate analyses were utilized to evaluate test characteristics and predictors of teratoma.Both serum miR-375-3p and miR-375-5p exhibited poor performance (miR-375-3p: 86% sensitivity, 32% specificity, AUC: 0.506; miR-375-5p: 55% sensitivity, 67% specificity, AUC: 0.556). Teratoma at orchiectomy was the only predictor of PC-RPLND teratoma. Small RNA sequencing identified three potentially discriminatory miRNAs, but further validation demonstrated no utility. Our results confirm prior reports that serum miR-375 cannot predict teratoma, and suggest that there may not exist a predictive serum miRNA for teratoma. Patient summary: We found that serum miR-375 cannot detect the presence of teratoma at postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). We are also unable to find any other serum miRNAs predictive of pure teratoma at PC-RPLND. Hence, the lack of a reliable circulating marker of teratoma remains a critical clinical need.http://www.sciencedirect.com/science/article/pii/S2666168321000380Retroperitoneal lymph node dissectionMicroRNATeratomaSerum biomarker |
| spellingShingle | John T. Lafin Alexander P. Kenigsberg Xiaosong Meng Dreaux Abe Anna Savelyeva Nirmish Singla Solomon L. Woldu Yair Lotan Ryan J. Mauck Cheryl M. Lewis Vitaly Margulis Daniel Wong Liwei Jia Payal Kapur Lin Xu Ryan W. Speir Gregory T. Chesnut A. Lindsay Frazier Douglas W. Strand Nicholas Coleman Matthew J. Murray James F. Amatruda Aditya Bagrodia Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection European Urology Open Science Retroperitoneal lymph node dissection MicroRNA Teratoma Serum biomarker |
| title | Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection |
| title_full | Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection |
| title_fullStr | Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection |
| title_full_unstemmed | Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection |
| title_short | Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection |
| title_sort | serum small rna sequencing and mir 375 assay do not identify the presence of pure teratoma at postchemotherapy retroperitoneal lymph node dissection |
| topic | Retroperitoneal lymph node dissection MicroRNA Teratoma Serum biomarker |
| url | http://www.sciencedirect.com/science/article/pii/S2666168321000380 |
| work_keys_str_mv | AT johntlafin serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT alexanderpkenigsberg serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT xiaosongmeng serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT dreauxabe serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT annasavelyeva serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT nirmishsingla serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT solomonlwoldu serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT yairlotan serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT ryanjmauck serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT cherylmlewis serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT vitalymargulis serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT danielwong serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT liweijia serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT payalkapur serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT linxu serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT ryanwspeir serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT gregorytchesnut serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT alindsayfrazier serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT douglaswstrand serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT nicholascoleman serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT matthewjmurray serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT jamesfamatruda serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection AT adityabagrodia serumsmallrnasequencingandmir375assaydonotidentifythepresenceofpureteratomaatpostchemotherapyretroperitoneallymphnodedissection |